Diltiazem cream: Completed Phase III enrollment

Ventrus completed enrollment of 434 patients with anal fissures in a double-blind, placebo-controlled, international Phase III trial evaluating thrice-daily 2%

Read the full 207 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE